Now is the time. There is a growing clinical body of evidence which suggests antibodies that optimally target misfolded proteins can result in clinically meaningful benefit for patients. With a growing pipeline of programs based on this scientific approach, Prothena is advancing a number of novel therapeutics for neurodegenerative and rare peripheral amyloid diseases.
We follow the science. Fueled by a deep scientific expertise built over decades, our research has led to foundational discoveries related to diseases caused by protein dysregulation.
The need for transformative medicines is greater than ever. We integrate scientific insights around neurological dysfunction and the biology of misfolded proteins to advance a diverse pipeline of novel therapeutics.
Clinical data reveals our path forward for new therapies with the potential for profound advances for patients.
